News Sentiment

EDSA sentiment intelligence

Edesa Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.01 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.5% over one week, +20.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

[EFFECT] Edesa Biotech, Inc. SEC Filing

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend active 20.9% over four weeks
Fair value 80.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 31
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 7
TradingView 6
TradingKey 4
GlobeNewswire 4
Moomoo 3
Stocktwits 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 13
Deals and strategy 4
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Stock Titan Direct company coverage

[EFFECT] Edesa Biotech, Inc. SEC Filing

This article announces an EFFECT SEC filing for Edesa Biotech, Inc. (EDSA), indicating the effectiveness of an S-3 Shelf Registration Statement. The filing has a neutral impact and sentiment, and the notice of effectiveness specifies July 13, 2026, as the effective date. The arti

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 09:41
Source
Stock Titan
Stock Titan Direct company coverage

Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resale

Edesa Biotech (EDSA) has registered 729,241 common shares for resale by existing investors who participated in a June 2026 private placement, raising approximately $3.5 million. The company itself will not receive any proceeds from these resales, as the original private placement

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSA

This article focuses on the enterprise value to EBIT forward for Edesa Biotech, Inc. (NASDAQ: EDSA). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics and market performance.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 09:11
Source
TradingView
Stock Titan Direct company coverage

Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant

Edesa Biotech's CEO, Pardeep Nijhawan, was granted 3,378 restricted share units (RSUs) which vested immediately under the company's 2019 Equity Incentive Compensation Plan. This grant increases his direct holdings to 888,062 common shares. The Form 4 filing also details his indir

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Edesa Biotech (NASDAQ: EDSA) registers 729,241 shares for resale

Edesa Biotech Inc. (NASDAQ: EDSA) has filed an S-3 registration statement to allow for the resale of up to 729,241 common shares. These shares were issued in a recent private placement that closed on June 16, 2026, generating approximately $3.5 million for the company, but Edesa

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Zacks Small Cap Research Direct company coverage

EDSA: Positive Exploratory Data in Patients with AKI

Edesa Biotech, Inc. (EDSA) announced positive exploratory data for its drug paridiprubart (EB05) in patients with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS), showing a significant 32% relative reduction in 28-day mortality and a 23% relative reductio

Tone
Positive 76/100
Event
Market update
Published
02 Jul 2026 16:40
Source
Zacks Small Cap Research
Moomoo Direct company coverage

Brookline Capital Initiates Edesa Biotech(EDSA.US) With Buy Rating, Announces Target Price $21

Brookline Capital has initiated coverage on Edesa Biotech (EDSA.US) with a Buy rating. The firm has set a price target of $21 for Edesa Biotech's stock. This initiation and target price announcement suggest a positive outlook for the company from Brookline Capital.

Tone
Positive 92/100
Event
Analyst action
Published
29 Jun 2026 21:40
Source
Moomoo
Investing.com Direct company coverage

Brookline initiates Edesa Biotech stock with buy on pipeline

Brookline Capital Markets has initiated coverage on Edesa Biotech (NASDAQ: EDSA) with a buy rating and a price target of $21.00, citing the company's promising pipeline which includes EB06 for vitiligo and a Phase 3-ready asset, EB01, for allergic contact dermatitis. The firm als

Tone
Positive 82/100
Event
Analyst action
Published
29 Jun 2026 20:39
Source
Investing.com
TradingView Direct company coverage

Edesa Biotech, Inc. Actuals & Estimates (NASDAQ:EDSA)

This article provides an overview of Edesa Biotech, Inc. (EDSA) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net income figures. The

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Edesa Biotech, Inc. – NASDAQ:EDSA

This page provides financial information for Edesa Biotech, Inc. (NASDAQ: EDSA), specifically focusing on its Price to Book Forward metric. The content indicates that the market was closed at the time of viewing, with no trades executed for the company. The page is from TradingVi

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Edesa Biotech, Inc. – NASDAQ:EDSA

This article briefly mentions the "Price to sales forward" metric for Edesa Biotech, Inc. (NASDAQ: EDSA), indicating it's a financial data point available on TradingView. The page appears to be a financial overview or data display page for the company on the platform.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:39
Source
TradingView
Simply Wall Street Direct company coverage

CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares

Pardeep Nijhawan, CEO of Edesa Biotech, recently purchased US$800k worth of company stock at an average price of US$5.21, increasing his holding by 28%. This was the largest insider purchase in the last year, with insiders being net buyers overall despite making previous investme

Tone
Positive 65/100
Event
Market update
Published
19 Jun 2026 12:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group

A Schedule 13G filing reveals that a group of related entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, collectively hold a 5.4% beneficial ownership in Edesa Biotech (EDSA). This stake, a

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 20:40
Source
Stock Titan
TradingKey Direct company coverage

Edesa Biotech Inc (EDSA) Institutional Confidence

The article analyzes the institutional confidence in Edesa Biotech Inc (EDSA), noting a current shareholding score of 3.00, placing it 193rd out of 388 in its industry. Institutional shareholding proportion increased by 52.45% quarter-over-quarter to 49.07%. Steven Cohen is ident

Tone
Positive 58/100
Event
Market update
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Edesa Biotech Inc (EDSA), detailing its current risk score, beta value, and various volatility metrics. The company ranks 233 out of 388 in the Biotechnology & Medical Research industry with a risk assessment score of 2.19. Key metrics

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Edesa Biotech Inc (EDSA), highlighting its current earnings forecast score, average analyst price target of $9.00, and a "Buy" trend based on 2 analysts. It also details the company's recent and expected EPS performance and compares i

Tone
Positive 74/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Edesa Biotech Inc.'s (EDSA) dividend history and stock splits. It notes that the company has not distributed any dividends in the past five years and details a 7-for-1 reverse merger stock split that occurred on October 10, 2023. The article a

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:10
Source
TradingKey
Stock Titan Direct company coverage

Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase

Edesa Biotech's CEO, Pardeep Nijhawan, privately purchased 153,550 common shares at $5.21 each, totaling $799,995.50, increasing his direct holdings to 884,684 shares. This strategic investment, noted in a Form 4 SEC filing, signifies a significant commitment to the company. The

Tone
Positive 66/100
Event
Market update
Published
16 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Nijhawan lifts Edesa Biotech (EDSA) beneficial ownership stake to 19.99%

Dr. Pardeep Nijhawan has increased his beneficial ownership in Edesa Biotech, Inc. (EDSA) to 19.99% through various transactions including restricted stock unit grants, open-market purchases, and a private placement. This updated ownership of 2,210,022 common shares is detailed i

Tone
Positive 64/100
Event
Deals and strategy
Published
16 Jun 2026 21:09
Source
Stock Titan
Stocktwits Direct company coverage

Why Did EDSA Stock Rally More Than 70% Today?

Edesa Biotech's stock surged over 70% after reporting positive late-stage study results for its experimental drug, paridiprubart, which showed a statistically significant reduction in mortality for Acute Respiratory Distress Syndrome (ARDS) patients. The company is now pursuing r

Tone
Positive 95/100
Event
Earnings
Published
14 Jun 2026 04:09
Source
Stocktwits
Quiver Quantitative Direct company coverage

Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical Programs

Edesa Biotech, Inc. has secured approximately $3.5 million through a private investment in public equity (PIPE) financing. This funding, involving the sale of common shares to investors and the CEO, is intended to advance the company's vitiligo program, support its drug candidate

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:41
Source
Quiver Quantitative
TradingView Direct company coverage

Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares

Edesa Biotech has successfully raised $3.5 million through a private placement, issuing 729,241 common shares to various investors including its CEO, with prices set at $4.69 and $5.21 respectively. The company also entered a Registration Rights Agreement, committing to file resa

Tone
Positive 72/100
Event
Market update
Published
11 Jun 2026 13:39
Source
TradingView
GlobeNewswire Direct company coverage

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Edesa Biotech, Inc. announced a private placement (PIPE) financing expected to generate approximately $3.5 million in gross proceeds. The investment, which includes participation from Edesa's CEO and healthcare-focused investors, will fund the advancement of the company’s vitilig

Tone
Positive 67/100
Event
Market update
Published
11 Jun 2026 13:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO

Edesa Biotech has announced a private placement (PIPE) financing expected to raise approximately $3.5 million. The company will sell 729,241 common shares, with its CEO purchasing shares at a slightly higher price than other investors, demonstrating insider participation. Proceed

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

CEO backs $3.5M raise to advance Edesa vitiligo work

Edesa Biotech has announced a $3.5 million private placement of common shares, led by its CEO and healthcare-focused investors. The proceeds will be used to advance the company's vitiligo program and its drug candidate paridiprubart, as well as for general corporate purposes. The

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding

Edesa Biotech, Inc. is set to receive $3.42014 million in funding through a private placement of 729,241 common shares at $4.69 per share. The transaction, expected to close on June 15, 2026, includes participation from the company's CEO and healthcare-focused investors. This fun

Tone
Positive 72/100
Event
Guidance
Published
10 Jun 2026 15:09
Source
www.marketscreener.com